Kornimate/medical-research-clean huggingface dataset:
cytoreduction followed by normothermic versus hyperthermic intraperitoneal intraoperative chemoperfusion (hipec): a study in peritoneal carcinomatosis

Conditions: Peritoneal Carcinomatosis

Summary: peritoneal carcinomatosis from appendix or colon (large bowel) cancer is treated in suitable patients with surgery followed by instillation of heated chemotherapy inside the abdominal cavity. this procedure is termed 'hyperthermic intraoperative peritoneal chemoperfusion' or hipec. many center perform hipec with high dose oxaliplatin, a standard chemotherapy drug active against colon cancer, administered during 30 minutes at 41°c. the hypothesis of this study is, that chemoperfusion at normal (37.5°c) temperature but longer duration (90 minutes) may be safer and at least as efficient. patients will be treated with one of three possible hipec regimens using oxaliplatin: high dose, 30 min, 41°c; high dose, 30 min, 37.5°c; or low dose, 90 min, 37.5°c. the outcome parameters are pharmacokinetic and pharmacodynamic: using specialized techniques, tissue penetration of chemotherapy and cancer cell kill effects will be compared in order to establish the safest and most active hipec regimen.


Eligibility criteria:
inclusion criteria: * patients with peritoneal carcinomatosis from colorectal origin (including appendiceal mucinous neoplasms and the pseudomyxoma syndromes) amenable for cytoreduction and hipec. exclusion criteria: * no written informed consent * irresectable and/or metastatic disease found during surgery * known allergy to oxaliplatin

Keywords: peritoneal carcinomatosis from colorectal or appendiceal origin
safety and efficacy study of the ng shield, a device intended to reduce pain and discomfort level related to nasogasstric tube usage

Conditions: Intubation, Nasogastric

Summary: the purpose of the study i to demonstrate the safety and efficacy of a device that intends to reduce pain/discomfort related to nasogfastric tube usage by reducing the friction between the tube and internal orifice (nose and pharynx)using micro vibrations


Eligibility criteria:
inclusion criteria: 1. subject is in good health and able to undergoes the ng tube insertion procedure, according to the pi decision 2. subject is able to understand and answer the pain and discomfort questionnaires 3. subject has been fasting for at least 12h prior to the insertion phase 4. subject underwent a physical examination by the pi 5. subject able, agrees and signs the inform consent form (icf) exclusion criteria: 1. subject has any history of dysphagia or esophageal disease 2. subject used anti pain medications during the last week prior to the study date 3. subject used antibiotics during the last week prior to the study date 4. subject with asthma 5. subject with chronic or acute nasal or throat disorder 6. subject who suffered from upper respiratory infection at least 7 days prior to the insertion procedure 7. any pain from other source prior to the initiation of the study procedure according to the pi judgment and decision 8. subject has any condition, which precludes compliance with study and/or device instruction for use 9. subject is currently participating in another clinical study

Keywords: enteral feeding subject who requires nasogastric tube
segmentation of structural abnormalities in chronic lung diseases

Conditions: Cystic Fibrosis; Asthma; COPD; Interstitial Lung Disease

Summary: lung structural abnormalities are complex, time-consuming, and may lack reproducibility to evaluate visually on ct scans. the study's aim is to perform automated recognition of structural abnormalities in ct scans of patients with chronic lung diseases by using dedicated software.

three chronic lung diseases will constitute the target of the study, by using retrospective data from each lung disease: * cystic fibrosis * asthma and copd * interstitial lung diseases dedicated algorithms will be developped for each disease condition.

Eligibility criteria:
inclusion criteria: * patients with chronic lung disease and clinical examination, pulmonary function test, and ct acquired during a routine follow-up
effectiveness of instrumental rehabilitation in patients with adhesive capsulitis

Conditions: Adhesive Capsulitis of the Shoulder

Summary: the aim of this study is to evaluate the effectiveness of robotic training compared to conventional rehabilitation in patients with ac.

nowadays, rehabilitation focuses on functional work during physiotherapy sessions to improve the patient's autonomy. in the era of new technologies, robotics and virtual reality have shown great interest in functional rehabilitation and cortical reorganization.

Eligibility criteria:
inclusion criteria: * patients \>18 years of age * shoulder pain and/or movement limitation * idiopathic ac or associated with confirmed systemic disease (e.g., diabetes or dyslipidemia) exclusion criteria: * cognitive impairment * history of surgery * fracture or dislocation of the shoulder * history of shoulder tendinopathy * history of inflammatory or degenerative disease * infection * neurological disease (parkinson's disease, stroke, multiple sclerosis, neurological * manipulation under anesthesia, hydro dilation, platelet rich plasma or hyaluronic acid infiltration within the last 6 months

Keywords: adhesive capsulitis rehabilitation robotic training
abraxane and gemcitabine versus gemcitabine alone in locally advanced unresectable pancreatic cancer.

Conditions: Pancreatic Cancer Stage II

Summary: pancreatic cancer is the fourth cause of cancer mortality: there are different treatment approaches to locally advanced pancreatic cancer management. generally, gemcitabine alone is considered a reasonable approach for advanced pancreatic cancer patients but we need a chemotherapeutic regimen able to prevent as much as possible a progression of the disease. nab-paclitaxel (abraxane) recently demonstrated an interesting activity profile in advanced pancreatic cancer. a combination of nab-paclitaxel and gemcitabine has been demonstrated superior to gemcitabine alone in metastatic patients.

study population: locally advanced unresectable pancreatic cancer patients elegibility criteria: * written informed consent * age \>18 \< 75 years * histologically/cytologically confirmed locally advanced, unresectable pancreatic cancer * at least one lesion measurable with ct or mri scan * performance status (ecog) 0-1 at study entry * life expectancy of at least 3 months * adequate marrow, liver and renal function * effective contraception if the risk of conception exists (in the informed consent for the patients the descriptions of possible contraceptives is reported

Eligibility criteria:
inclusion criteria: * written informed consent * age \>18 \< 75 years * histologically/cytologically confirmed locally advanced, unresectable pancreatic cancer * at least one lesion measurable with ct or mri scan * performance status (ecog) 0-1 at study entry * life expectancy of at least 3 months * adequate marrow, liver and renal function * effective contraception if the risk of conception exists (in the informed consent for the patients the descriptions of possible contraceptives is reported) exclusion criteria: * previous chemotherapy or radiotherapy for pancreatic cancer * severe cardiovascular disease * thrombotic or embolic events * acute or subacute intestinal occlusion or history of inflammatory bowel disease * known hypersensitivity to study drug * known drugs or alcohol abuse * pregnant or breastfeeding women * previous or concurrent malignancy; except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and with evidence of no recurrence for at least 5 years prior to randomization * unable to sign informed consent

Keywords: pancreatic cancer locally advanced unresectable cancer
visual feedback in lower limb rehabilitation

Conditions: Brain Injuries; Brain Injuries, Traumatic; Brain Injuries, Vascular

Summary: severe acquired brain injury (sabi) is defined as "an encephalic impairment that occurs after birth and is not related to a congenital or degenerative disease. this impairment may be temporary, or permanent, and cause partial or functional disability or psychosocial distress." in italy there are at least 10-15 new cases of sabi per year per 100,000 inhabitants; the estimated prevalence is about 150,000 cases per year. often, people with sabi present focal neurological deficits, including alterations in strength, sensitivity, coordination and gait. most of the rehabilitation protocols for people with sabi are derived from post-stroke studies, caused by lack of evidence on specific rehabilitation of people with sabi. rehabilitation of people with sabi should begin as soon as possible, to prevent the onset of retractions and decubitus, and to regain joint mobility, strength, and coordination. omego® (tyromotion) is a newly developed device used in lower extremity rehabilitation, that provides visual and auditory feedback. specifically, omego® contains several games developed to enhance and promote learning behaviors, that simulate activities of daily living. the use of devices such as cycle ergometers is recommended in the rehabilitation of people with sabi; however, there are no studies demonstrating the effect of cycle ergometer training in association with visual feedback. the purpose of this study is to evaluate, both in people without apparent pathology (hereafter identified as "healthy") and in people with sabi, whether visual feedback during omego® exercise modifies brain connectivity, emotional drive, and lower limb performance during a lower limb-specific motor rehabilitation task.


Eligibility criteria:
inclusion criteria: * diagnosis os severe acquired brain injury (sabi) * trunk control test score greater or equal to 48 * motricity index lower limb score greater or equal to 18 * clinical stability * patient/caregiver ability to understand ans sing the informed consent exclusion criteria: * disorder of consciousness (mininally concious state or vegetative state) * severe visual impairment (central or peripheral, prior or acquired after the scute event) * presence of severe cognitive impairment * presence of global aphasia or presence of severe apraxia

Keywords: acquired brain injury traumatic virtual reality cognitive function rehabilitation disability lower limb personalized medicine
the individualized accurate diagnosis and treatment of chronic objective pulmonary disease(copd) patients based on multidimensional data

Conditions: Copd; Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is known as progressive lung disease and the fourth leading cause of death worldwide. despite valuable efforts, there is still no individualized accurate diagnostic and prognostic tool for copd. hence, the investigators' research integrated multi-dimensional data of copd patients, which may provide an invaluable bioinformatic resource for understanding the underlying molecular alterations that drive disease progression, with the goal of developing individualized accurate diagnostic and therapeutic inventions.

chronic obstructive pulmonary disease (copd) is known as progressive lung disease and the fourth leading cause of death worldwide. acute exacerbations of copd (aecopd) is an important event of disease progression worsening in airway function and respiratory symptoms, bringing about respiratory failure, and increasing the rates of mortality. despite valuable efforts, there is still no individualized accurate diagnostic and prognostic tool for copd. in this context, the investigators are to perform comprehensive transcriptomic, proteomic, metabonomic and exosome characterization of copd patients and healthy controls. biological samples of copd participants, including blood, urine, stool, saliva, bronchoalveolar lavage fluid and clinical characteristics are going to be collected from the remaining materials of the routine clinical examination. and samples of healthy controls will be collected from the rest of the healthy examination practice. by integrating the multi-dimensional data, the investigators aim to elucidate the impact of molecular alterations driving phenotypic variation and to delineate the mechanisms of aecopd for prospective exploration of personalized, precision-based clinical care.

Eligibility criteria:
inclusion criteria: 1. patient has signed informed consent. 2. patients diagnosed with copd or fully healthy participants. exclusion criteria: 1. tumor disease. 2. heart disease. 3. thyroid disease.
become of patients infected or suspected of being infected by covid-19 and supported by the ghpsj and the establishments of the paris plaisance hospital city

Conditions: COVID

Summary: the ongoing coronavirus (covid-19) pandemic is causing a major global health crisis and is shaking up hospital organizations. to date, the recognized risk factors for severe forms of covid-19 infection are elderly patients (\> 70 years), obese patients, patients with chronic renal or respiratory pathologies, cardiovascular history (stroke or coronary artery disease), chronic respiratory conditions, high blood pressure, diabetes, and cancer. covid-19 is manifested by a risk of acute respiratory distress syndrome requiring management by invasive ventilation. the lethality of this infection is around 4% in the current data. drastic precautionary measures for the transmission of the virus, as well as the provision of critical care beds by canceling any scheduled non-urgent intervention or consultation, have shaken up the hospital organization. in this context, it is essential to have forward-looking data in real time to adjust the care offer and better understand the impact of covid-19 on the patient populations treated.


Eligibility criteria:
inclusion criteria: - patient (of all ages) with symptoms compatible with infection by covid-19 treated at the ghpsj or in one of the establishments in the paris plaisance hospital city. exclusion criteria: * asymptomatic patient * patient objecting to the use of their data
modal anatomy of the ethmoid bone

Conditions: Anatomic Abnormality

Summary: the creation of a 3d model of modal anatomy of the ethmoid could, like other parts of the body, improve anatomical, radiological and perhaps even surgical learning. anatomical variations might constitute a "background noise" of the modal anatomy, which can be attenuated by multiplying the instances of acquisitions. the objective of this work is to establish modal anatomy of the ethmoid by the analysis of a large number of ct-scan acquisitions carried out in individuals with no acquired sinus pathology.

non-interventional descriptive research. sinus ctscans (period 2016-2019) will be reviewed from the pacs database of the chru of nancy and selected in individuals without sinus pathology. all ct-scans will be fully anonymized. 26 landmarks will be pointed out to enable : 1. prior images alignment (centering on the median line, realignment rotations then resizing) 2. a mean and median calculation, allowing to establish a mean and median ethmoid model 3. calculation of standard deviations for each voxel the structures obtained in this way (bone, tissue or aerial) will be described anatomically.

Eligibility criteria:
retrospective analysis of sinus ct scans images from individuals (period 2016-2019) inclusion criteria: all individuals (\>18 years all) with a sinus ct scan available in the chru database exclusion criteria: inflammatory sinus disease (eg. nasal polyposis, aspergilloma, ...) evolutive sinus tumor anatomical abnormality (e.g. post traumatic, prior sinus surgery, embryologic abnormality...)
paclitaxel-coated balloons in femoral indication to defeat restenosis

Conditions: Peripheral Artery Disease

Summary: the aim of the study is correlating efficacy of the treatment to the proportion of paclitaxel-dose supplied by the catheter. forty-five patients each will be treated by paclitaxel-coated or uncoated conventional balloon catheters in randomized order in 3 study centers. main inclusion criteria are rutherford class 2 - 5, ≥70% stenosis or occlusion in the superficial femoral or popliteal artery, main exclusion criteria are related to the use of paclitaxel and the need for follow-up examinations. either clinical or angiographic follow-up examinations are planned 6, 12 and 24 months following the intervention. primary endpoint is 6-month angiographic late lumen loss. secondary endpoints are further angiographic and clinical efficacy and various safety criteria.

paclitaxel-coated balloons have been shown to reduce late lumen loss, restenosis rates and the need for repeat target lesion revascularization compared to conventional uncoated balloon catheters. the aim of the study is correlating efficacy of the treatment to the proportion of paclitaxel-dose supplied by the catheter. to this end paclitaxel loss of catheters in the introductory sheaths and residual paclitaxel on used balloons will be determined and correlated to individual data indicating inhibition of neointimal proliferation. according to the study protocol 45 patients each will be treated by paclitaxel-coated or uncoated conventional balloon catheters in randomized order in 3 study centers. main inclusion criteria are rutherford class 2 - 5, ≥70% stenosis or occlusion in the superficial femoral or popliteal artery, 3 to 30 cm of length; beyond common contraindications against pta main exclusion criteria are related to the use of paclitaxel and the need for follow-up examinations. patients will be blinded against treatment. blinding of investigators after assignment of a patient to a treatment is not possible due to differences in the appearance of coated and uncoated catheters. either clinical or angiographic follow-up examinations are planned 6, 12 and 24 months following the intervention. primary endpoint is 6-month angiographic late lumen loss evaluated by a blinded independent core lab. secondary endpoints are interventional success rate, restenosis rates, minimal lumen diameter, target lesion revascularization, change in rutherford class, change in ankle-brachial-index, major amputations, a composite safety endpoint (defined as mae =death of any cause, target limb amputation, clinically / dus driven tlr) and all kinds of serious adverse events possibly related to the treatment.

Eligibility criteria:
inclusion criteria: * adult patients with paod, rutherford stage 2-5, occlusion or stenosis \>70% in diameter of at least 3 cm length in the superficial femoral artery and/ or popliteal artery exclusion criteria: * acute thrombus or aneurysm in the index limb/ vessel * doubts in the willingness or capability of the patient to allow follow up examination

Keywords: pavk pta drug coated balloon
fluoxetine for visual recovery after ischemic stroke

Conditions: Acute Stroke; Visual Field Loss

Summary: the purpose of this study is to determine whether fluoxetine, a selective serotonin reuptake inhibitor commonly used for depression, enhances visual recovery after an acute ischemic stroke.


Eligibility criteria:
inclusion criteria: * mri-confirmed acute ischemic stroke resulting in an isolated homonymous visual field loss. exclusion criteria: * known hypersensitivity to fluoxetine or other selective serotonin reuptake inhibitors * national institutes of health stroke scale score greater than 5 * premorbid modified rankin scale score greater than 2 * premorbid monocular or binocular visual field deficits * premorbid retinopathy or optic neuropathy * premorbid depression * history of cognitive impairment, dementia, or neurodegenerative disorder * history of seizure disorder * history of mania or hypomania * history of hyponatremia * history of angle-closure glaucoma or elevated intraocular pressure * current alcohol abuse or impaired liver function * current use of an antidepressant medication * current use of a medication likely to have an adverse interaction with fluoxetine * current use of a medication likely to impair post-stroke recovery * contraindication to mri * pregnancy or lactation * hemorrhagic transformation of the index stroke, resulting in mass effect * enrollment in another clinical trial at the time of the index stroke

Keywords: acute ischemic stroke homonymous hemianopia homonymous quadrantanopia visual field loss post-stroke recovery fluoxetine selective serotonin reuptake inhibitor
safety, tolerability and efficacy of yh14618 in patients with degenerative disc disease

Conditions: Degenerative Disc Disease

Summary: the objective of this study is to assess the safety and tolerability of yh14618 during 24 weeks of follow-up period after single administration in patients with degenerative disc disease.


Eligibility criteria:
inclusion criteria: * have signed a written informed consent voluntarily, prior to the any procedure * degenerative disc disease patients of aged over 20 years * have one or more of the symptomatic lumbar level(l1\~s1) as confirmed using radiology(x-ray, mri and/or discogram/ct) * have been diagnosed 2\~3 degree of mri index by modified thompson classification * oswestry diability index(odi) of 30 or greater * visual analog scale(vas) of 4 or greater exclusion criteria: * subjects unable to have radiological examination * have history of neurological disease, herniated lumbar disc, compression fractures and lumbar spinal surgery * sacroiliac joint dysfunction * have been treated with any drugs for pain control within 7 days prior to the first administration * hypersensitivity to drugs * pregnant women, nursing mothers or subjects who do not agree to assigned contraception in the study * participated in any other clinical trials within 30 days prior to the first administration

Keywords: degenerative disc disease yh14618 penial 2000 penial 2k
noninvasive brain stimulation on memory in individuals with mild cognitive impairment and history of brain injury

Conditions: Amnestic Mild Cognitive Impairment; Traumatic Brain Injury; Mild Traumatic Brain Injury

Summary: the study will examine the efficacy of high definition transcranial direct current stimulation (hd-tdcs) and its influence on episodic memory in patients with amnestic mild cognitive impairment and a history of traumatic brain injury. ten sessions of hd-tdcs to the dorsal anterior cingulate region is expected to result in improvements in episodic memory measures immediately following the last session and at a 3-month follow-up.


Eligibility criteria:
inclusion criteria: * age 50 and older * native english speakers * 12 years of education or higher * active diagnosis of amci * history of tbi based on va/dod criteria exclusion criteria: * tbi within the past 2 years * lifetime history of stroke, transient ischemic attack, heart attack, or congestive heart failure * lifetime history of epilepsy * major psychiatric disorders (i.e., posttraumatic stress disorder, bipolar disorder, schizophrenia) * substance use disorder * has metal fragments in head * taking medications that may interact with the hd-tdcs effect (i.e., amphetamines, l-dopa, carbamazepine, sulpiride, pergolide, lorazepam, dextromethorphan, d-cycloserine, flunarizine, or ropinirole)